Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 4/2010

01-08-2010 | Commentary

Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...

Authors: Manu Shankar-Hari, Duncan Wyncoll

Published in: Critical Care | Issue 4/2010

Login to get access

Abstract

Severe acute pancreatitis (SAP) is characterized by an unregulated systemic proinflammatory response secondary to activation of trypsin within the pancreatic tissue, resulting in multiple organ failure. This dysregulated inflammation leading to organ dysfunction also characterizes severe sepsis. Activated protein C (APC) has pleotropic effects on the immune, coagulation, inflammatory and apoptotic pathways, and has been postulated to benefit acute pancreatitis - although concerns of possible retroperitoneal bleeding remain. Currently, experimental studies and subgroup data on patients with pancreatitis from a randomized controlled trial of APC in severe sepsis form the literature on the possible role of APC in SAP. We review the first randomized controlled trial of APC in acute pancreatitis published in the present issue of Critical Care.
Literature
1.
Pettila V, Kyhala L, Kylanpaa M-J, Leppaniemi A, Tallgran M, Markkola A, Puolakkainen P, Kemppainen E: APCAP - activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care 2010, 14: R139. 10.1186/cc9203PubMedCentralCrossRefPubMed
2.
Radenkovic D, Bajec D, Karamarkovic A, Stefanovic B, Milic N, Ignjatovic S, Gregoric P, Milicevic M: Disorders of hemostasis during the surgical management of severe necrotizing pancreatitis. Pancreas 2004, 29: 152-156. 10.1097/00006676-200408000-00010CrossRefPubMed
3.
Ping C, Youngping Z, Minmin Q, Weiyan Y, Yaozong Y: Activated protein C improves severity of acute pancreatitis via up-regulating the expressions of endothelial cell protein C receptor and thrombomodulin. Dig Dis Sci 2010, 55: 1599-1609. 10.1007/s10620-009-0909-yCrossRefPubMed
4.
Alfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernandez-del Castillo C: Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006, 141: 670-676. 10.1001/archsurg.141.7.670CrossRef
5.
Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand J-A, Skerett SJ, Stapleton RD, Ware LB, Waldmann CS: Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004, 32: 2524-2536. 10.1097/01.CCM.0000148222.09869.92CrossRefPubMed
6.
Khan A, Agarwal R, Aggarwal AN, Gupta D: Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis. Respir Care 2010, 55: 901-910.PubMed
7.
8.
Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL, Xigris and prophylactic heparin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecoginalfa (activated). Am J Respir Crit Care Med 2007, 176: 483-490. 10.1164/rccm.200612-1803OCCrossRefPubMed
9.
Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Gardlund B, Marshal JC, Rhodes A: Design, conduct, analysis and reporting of a multi-national, placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34: 1935-1947. 10.1007/s00134-008-1266-6PubMedCentralCrossRefPubMed
10.
Shorr AF, Nelson DR, Wyncoll DLA, Reinhart K, Brunkhorst F, Vail GM, Janes J: Protein C: a potential biomarker in severe sepsis an a possible tool for monitoring treatment with drotrecogin alfa (activated). Crit Care 2008, 12: R45. 10.1186/cc6854PubMedCentralCrossRefPubMed
11.
Ottesen LH, Bladbjerg EM, Osman M, Lausten SB, Jacobsen NO, Gran J, Jensen SL: Protein C activation during the initial phase of experimental acute pancreatitis in the rabbit. Dig Surg 1999, 16: 486-495. 10.1159/000018774CrossRefPubMed
Metadata
Title
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ...
Authors
Manu Shankar-Hari
Duncan Wyncoll
Publication date
01-08-2010
Publisher
BioMed Central
Published in
Critical Care / Issue 4/2010
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9190

Other articles of this Issue 4/2010

Critical Care 4/2010 Go to the issue

Letter

Quality of life in patients aged 80 or over after intensive care unit discharge

Journal club critique

Clearing up the confusion: The results of two pilot studies of antipsychotics for ICU delirium

Research

Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes

Research

Positive end-expiratory pressure affects the value of intra-abdominal pressure in acute lung injury/acute respiratory distress syndrome patients: a pilot study

Research

Interferon-β attenuates lung inflammation following experimental subarachnoid hemorrhage

Research

The use of exenatide in severely burned pediatric patients